Acorda Therapeutics Historical PE Ratio image   This ACOR PE ratio history page last updated 4/18/2024
Acorda Therapeutics Historical PE Ratio Chart
PeriodPriceEarningsAnnualizedPE
Q3 2023
11/13/2023
9.57-7.16-28.64NA
Q2 2023
8/8/2023
16.50-7.55-30.20NA
Q1 2023
5/11/2023
16.80-13.80-55.20NA
Q4 2022
3/9/2023
16.2011.4045.600.4
Q3 2022
11/1/2022
16.00-11.00-44.00NA
Q2 2022
8/4/2022
10.60-63.00-252.00NA
Q1 2022
5/11/2022
14.80-33.20-132.80NA
Q4 2021
3/9/2022
45.00-13.40-53.60NA
Q3 2021
11/9/2021
75.20-28.60-114.40NA
Q2 2021
8/5/2021
82.00-37.40-149.60NA
Q1 2021
5/6/2021
94.20-49.20-196.80NA
Q4 2020
3/4/2021
135.60-50.00-200.00NA
Q3 2020
11/3/2020
129.60-27.60-110.40NA
Q2 2020
8/4/2020
76.80-42.00-168.00NA
Q1 2020
5/5/2020
112.80-61.20-244.80NA
Q4 2019
2/13/2020
230.40-18.00-72.00NA
Q3 2019
11/4/2019
240.00-55.20-220.80NA
Q2 2019
8/1/2019
728.40-66.00-264.00NA
Q1 2019
5/2/2019
1269.60-67.20-268.80NA
Q4 2018
2/14/2019
1867.2054.00216.008.6
Q3 2018
10/31/2018
2293.2020.4081.6028.1
Q2 2018
8/2/2018
3120.00168.00672.004.6
Q1 2018
5/2/2018
2784.0016.8067.2041.4
Q4 2017
2/15/2018
3012.0073.20292.8010.3
Q3 2017
10/31/2017
3189.6051.60206.4015.5
Q2 2017
7/27/2017
2604.0034.80139.2018.7
Q1 2017
4/27/2017
1866.00-9.60-38.40NA
Q4 2016
2/14/2017
2862.006.0024.00119.2
Q3 2016
10/27/2016
2190.00-4.80-19.20NA
Q2 2016
7/28/2016
2994.008.4033.6089.1
Q1 2016
4/28/2016
3280.808.4033.6097.6
Q4 2015
2/11/2016
4017.6033.60134.4029.9
Q3 2015
10/22/2015
4190.4037.20148.8028.2
Q2 2015
7/30/2015
4107.6037.20148.8027.6
Q1 2015
4/30/2015
3608.4018.0072.0050.1
Q4 2014
2/12/2015
4398.0055.20220.8019.9
Q3 2014
10/30/2014
4338.0033.60134.4032.3
Q2 2014
7/31/2014
3512.4050.40201.6017.4
Q1 2014
5/6/2014
3824.402.409.60398.4
Q4 2013
2/13/2014
4087.2018.0072.0056.8
Q3 2013
10/31/2013
3673.2045.60182.4020.1
Q2 2013
8/1/2013
4471.2030.00120.0037.3
Q1 2013
5/2/2013
4363.2010.8043.20101.0
Q4 2012
2/13/2013
3595.2028.80115.2031.2
Q3 2012
10/31/2012
2874.0045.60182.4015.8
Q2 2012
7/31/2012
2888.4032.40129.6022.3
Q1 2012
5/3/2012
2878.8022.8091.2031.6
Acorda Therapeutics PE History Chart
PeriodPriceEarningsTTMPE
Q3 2023
11/13/2023
9.57-7.16-17.11NA
Q2 2023
8/8/2023
16.50-7.55-20.95NA
Q1 2023
5/11/2023
16.80-13.80-76.40NA
Q4 2022
3/9/2023
16.2011.40-95.80NA
Q3 2022
11/1/2022
16.00-11.00-120.60NA
Q2 2022
8/4/2022
10.60-63.00-138.20NA
Q1 2022
5/11/2022
14.80-33.20-112.60NA
Q4 2021
3/9/2022
45.00-13.40-128.60NA
Q3 2021
11/9/2021
75.20-28.60-165.20NA
Q2 2021
8/5/2021
82.00-37.40-164.20NA
Q1 2021
5/6/2021
94.20-49.20-168.80NA
Q4 2020
3/4/2021
135.60-50.00-180.80NA
Q3 2020
11/3/2020
129.60-27.60-148.80NA
Q2 2020
8/4/2020
76.80-42.00-176.40NA
Q1 2020
5/5/2020
112.80-61.20-200.40NA
Q4 2019
2/13/2020
230.40-18.00-206.40NA
Q3 2019
11/4/2019
240.00-55.20-134.40NA
Q2 2019
8/1/2019
728.40-66.00-58.80NA
Q1 2019
5/2/2019
1269.60-67.20175.207.2
Q4 2018
2/14/2019
1867.2054.00259.207.2
Q3 2018
10/31/2018
2293.2020.40278.408.2
Q2 2018
8/2/2018
3120.00168.00309.6010.1
Q1 2018
5/2/2018
2784.0016.80176.4015.8
Q4 2017
2/15/2018
3012.0073.20150.0020.1
Q3 2017
10/31/2017
3189.6051.6082.8038.5
Q2 2017
7/27/2017
2604.0034.8026.4098.6
Q1 2017
4/27/2017
1866.00-9.600.00>500
Q4 2016
2/14/2017
2862.006.0018.00159.0
Q3 2016
10/27/2016
2190.00-4.8045.6048.0
Q2 2016
7/28/2016
2994.008.4087.6034.2
Q1 2016
4/28/2016
3280.808.40116.4028.2
Q4 2015
2/11/2016
4017.6033.60126.0031.9
Q3 2015
10/22/2015
4190.4037.20147.6028.4
Q2 2015
7/30/2015
4107.6037.20144.0028.5
Q1 2015
4/30/2015
3608.4018.00157.2023.0
Q4 2014
2/12/2015
4398.0055.20141.6031.1
Q3 2014
10/30/2014
4338.0033.60104.4041.6
Q2 2014
7/31/2014
3512.4050.40116.4030.2
Q1 2014
5/6/2014
3824.402.4096.0039.8
Q4 2013
2/13/2014
4087.2018.00104.4039.1
Q3 2013
10/31/2013
3673.2045.60115.2031.9
Q2 2013
8/1/2013
4471.2030.00115.2038.8
Q1 2013
5/2/2013
4363.2010.80117.6037.1
Q4 2012
2/13/2013
3595.2028.80129.6027.7
Q3 2012
10/31/2012
2874.0045.60NANA
Q2 2012
7/31/2012
2888.4032.40NANA
Q1 2012
5/3/2012
2878.8022.80NANA
Quotes delayed 20 minutes

Email EnvelopeFree ACOR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Acorda Therapeutics (ACOR) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

ACRS PE Ratio History
ACRV PE Ratio History
ACRX PE Ratio History
ACXP PE Ratio History
ADGI PE Ratio History
ADIL PE Ratio History
ADMA PE Ratio History
ADMP PE Ratio History
ADMS PE Ratio History
ADPT PE Ratio History
How should the ACOR historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Acorda Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this ACOR Historical PE Ratio page.

What is the average historical PE for ACOR based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The ACOR historical PE ratio using the annualized quarterly earnings method works out to 50.1.

What is the average historical PE for ACOR based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The ACOR historical PE ratio using the TTM earnings method works out to 38.2.

On this page we presented the Acorda Therapeutics Historical PE Ratio information for Acorda Therapeutics' stock. The average ACOR historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 50.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ACOR historical PE based on this TTM earnings result method is 38.2. Note: any PE calculations resulting in a value exceeding 500 were discarded as not meaningful. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ACOR historical PE result, against the recent PE: when this page was posted on 4/11/2024, the most recent closing price for ACOR had been 0.66, and the most recent quarterly earnings result, annualized, was 45.6. Meanwhile, the most recent TTM earnings summed to 175.2. From these numbers, we calculate the recent ACOR PE on 4/11/2024 based on annualized quarterly EPS was 0.0. Based on ACOR's history, that recent PE is low relative to the historical average, with the recent PE 100.0% lower than the historical average PE across our data set for Acorda Therapeutics. Looking at the recent ACOR PE on 4/11/2024 based on TTM EPS, we calculate the ratio at 0.0. Based on ACOR's history, that recent PE is low relative to the historical average, with the recent PE 100.0% lower than the average PE across our Acorda Therapeutics data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on ACOR or any other given stock, valuation analysis for ACOR can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Acorda Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ACOR. Thanks for visiting, and the next time you need to research ACOR Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: Funds Holding JXJT, CFFN Split History, Funds Holding DECN.

 

Acorda Therapeutics Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2024, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.